DCN as a therapeutic gene promotes the degradation of extracellular matrix (ECM) and attenuates transforming growth factor (TGF)-β-mediated immunosuppression to elevate CD4+ and CD8 T+ cells and simultaneously attenuate Treg accumulation in tumor tissues (Choi et al. 2010; Oh et al. 2017). This evidence concerns the gene TGFB1 and neoplasm.